Based on 2,246 unvaccinated volunteers at high risk of severe disease
The New York Times reported.
The drugmaker also said that its antiviral pill worked in laboratory studies against the omicron variant. Pfizer has asked the Food and Drug Administration to authorize Paxlovid. "It is a game changer," Pfizer CEO Albert Bourla told ABC News. "But at the same time, I want to emphasize that no one should use the existence of the pill as an excuse to avoid vaccination." The company said that the pill works best if given within three days of the onset of COVID-19 symptoms, according to the Times. The results were based on an analysis of 2,246 unvaccinated volunteers at high risk of severe disease.